Description
Ketorolacisanon-steroidalanti-inflammatorydrug(NSAID)thatexhibitsanti-inflammatoryandanalgesicactivities.KetorolacinhibitsCOX-1andCOX-2.Invivo,admiNISTrationofketorolacpreventsthespinalinjury-inducedincreaseofprotease-activatedreceptor1(PAR1)levelsanddecreasesactivationofspinalastrocytes,resultingindecreasedallodynia.Inspinalneurons,ketorolacdecreasessubstanceP-,calcitoningene-relatedpeptide-anddynorphin-immunoreactivity.Additionally,thiscompounddecreasesexpressionofphosphodiesterasetype4(PDE4D).
References
DongL,SmithJR,WinkelsteinBA.KetorolacreducesspinalastrocyticactivationandPAR1expressionassociatedwithattenuationofpainafterfacetjointinjury.JNeurotrauma.2013May15;30(10):818-25.PMID:23126437.
BendixenKH,Baad-HansenL,CairnsBE,etal.Effectsoflow-doseintramuscularketorolaconexperimentalpaininthemassetermuscleofhealthywomen.JOrofacPain.2010Fall;24(4):398-407.PMID:21197512.
WangXM,HamzaM,GordonSM,etal.COXinhibitorsdownregulatePDE4Dexpressioninaclinicalmodelofinflammatorypain.ClinPharmacolTher.2008Jul;84(1):39-42.PMID:18288087.
MaW,EisenachJC.IntraplantarinjectionofacyclooxygenaseinhibitorketorolacreducesimmunoreactivitiesofsubstanceP,calcitoningene-relatedpeptide,anddynorphininthedorsalhornofratswithnerveinjuryorinflammation.Neuroscience.2003;121(3):681-90.PMID:14568028.
